|Mr. Simon S. M. Chin MBA||Founder, Chairman, Chief Exec. Officer, Pres, Chief Financial Officer and Sec.||N/A||N/A||1959|
|Mr. James LeBlanc MBA||VP of Operations||N/A||N/A||1947|
|Dr. Paul Yaswen Ph.D.||Chief Scientific Officer||N/A||N/A||1958|
|Ms. Grace Osborne MBA||VP of Bus. Devel. & HR and Director||N/A||N/A||1967|
|Dr. Ronald Mark Gemberling M.D.||Chief Medical Officer||N/A||N/A||1947|
Iris BioTechnologies, Inc., a life science company, develops solutions for the detection and monitoring of monogenic and complex genomic diseases. It is developing nano-biochip technology platform used for the diagnosis and treatment of patients with breast cancer, neurological disorders, heart diseases, diabetes, and other gene-related metabolic problems. The company also develops BioWindows, an artificial intelligence system, which provides data and analysis for clinical applications, drug development, and stem cell research. Iris BioTechnologies, Inc. was founded in 1999 and is headquartered in Santa Clara, California.
Iris BioTechnologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.